Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Springworks Therapeutics Inc (SWTX)

Springworks Therapeutics Inc (SWTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,785,012
  • Shares Outstanding, K 74,386
  • Annual Sales, $ 5,450 K
  • Annual Income, $ -325,100 K
  • EBIT $ -300 M
  • EBITDA $ -299 M
  • 60-Month Beta 0.79
  • Price/Sales 517.98
  • Price/Cash Flow N/A
  • Price/Book 5.29

Options Overview Details

View History
  • Implied Volatility 57.33% ( -5.62%)
  • Historical Volatility 44.90%
  • IV Percentile 3%
  • IV Rank 13.94%
  • IV High 128.76% on 11/27/23
  • IV Low 45.76% on 09/03/24
  • Put/Call Vol Ratio 0.03
  • Today's Volume 62
  • Volume Avg (30-Day) 112
  • Put/Call OI Ratio 0.68
  • Today's Open Interest 7,742
  • Open Int (30-Day) 8,674

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.69
  • Number of Estimates 5
  • High Estimate -0.59
  • Low Estimate -0.78
  • Prior Year -1.44
  • Growth Rate Est. (year over year) +52.08%

Price Performance

See More
Period Period Low Period High Performance
1-Month
28.21 +29.65%
on 10/24/24
38.58 -5.20%
on 11/20/24
+6.09 (+19.96%)
since 10/21/24
3-Month
28.21 +29.65%
on 10/24/24
43.64 -16.19%
on 08/26/24
-2.94 (-7.45%)
since 08/21/24
52-Week
20.19 +81.14%
on 11/27/23
53.92 -32.17%
on 03/08/24
+15.43 (+72.93%)
since 11/21/23

Most Recent Stories

More News
Biotech Companies’ Q3 Updates: Promising Cancer Treatments on the Horizon

USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group News Commentary – As many biotech companies within the oncology space begin to roll...

ONCY : 0.9800 (-1.85%)
IOVA : 8.24 (+1.23%)
SNDX : 15.59 (-2.26%)
ONC.TO : 1.37 (-2.14%)
IBRX : 5.04 (+3.28%)
SWTX : 36.28 (-3.10%)
Biotech Companies' Q3 Updates: Promising Cancer Treatments on the Horizon

/CNW/ -- USA News Group News Commentary – As many biotech companies within the oncology space begin to roll out their end-of-quarter results, the American...

ONCY : 0.9800 (-1.85%)
IOVA : 8.24 (+1.23%)
SNDX : 15.59 (-2.26%)
ONC.TO : 1.37 (-2.14%)
IBRX : 5.04 (+3.28%)
SWTX : 36.28 (-3.10%)
SpringWorks' Q3 Loss Narrower Than Expected, Revenues Miss Mark

SpringWorks Therapeutics, Inc. SWTX incurred a loss of 72 cents per share in the third quarter of 2024, which was narrower than the Zacks Consensus Estimate of a loss of 76 cents. The company had reported...

IMCR : 32.11 (-0.96%)
CSTL : 28.85 (+1.41%)
ANIP : 55.79 (+1.25%)
SWTX : 36.28 (-3.10%)
SpringWorks Therapeutics to Participate in the Jefferies London Healthcare Conference

SWTX : 36.28 (-3.10%)
SpringWorks Therapeutics: Q3 Earnings Snapshot

SpringWorks Therapeutics: Q3 Earnings Snapshot

SWTX : 36.28 (-3.10%)
SpringWorks Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

SWTX : 36.28 (-3.10%)
SpringWorks Therapeutics Announces Mirdametinib Data to be Presented at the 2024 Society for Neuro-Oncology (SNO) Annual Meeting

SWTX : 36.28 (-3.10%)
SpringWorks Therapeutics Announces Publication of the Pivotal Phase 2b ReNeu Trial Evaluating Mirdametinib in Adults and Children with NF1-PN in the Journal of Clinical Oncology

SWTX : 36.28 (-3.10%)
SpringWorks Therapeutics Announces Long-Term Efficacy and Safety Data from Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors to be Presented at the Connective Tissue Oncology Society (CTOS) 2024 Annual Meeting

SWTX : 36.28 (-3.10%)
SpringWorks Therapeutics to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference

SWTX : 36.28 (-3.10%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

SpringWorks Therapeutics Inc. is a clinical-stage biopharmaceutical company. It is focused on developing life-changing medicines for patients with severe rare diseases and cancer. The company's product pipeline consists of Nirogacestat and Mirdametinib which are in clinical stage. SpringWorks Therapeutics...

See More

Key Turning Points

3rd Resistance Point 40.27
2nd Resistance Point 39.42
1st Resistance Point 38.43
Last Price 36.28
1st Support Level 36.60
2nd Support Level 35.75
3rd Support Level 34.76

See More

52-Week High 53.92
Fibonacci 61.8% 41.04
Fibonacci 50% 37.06
Last Price 36.28
Fibonacci 38.2% 33.08
52-Week Low 20.19

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar